Lupin targets $250 million in quarterly US sales in 3-4 years

Pharmaceutical giant Lupin is confident of surpassing $1 billion in US sales in the next few years. In an interview with CNBC-TV18, Ramesh Swaminathan, the company's Executive Director, Global CFO & Head of Corporate Affairs, said the company will be able to hit a quarterly sales run rate of $250 million in the US in 3-4 years from $200 million now.

Lupin expects a substantial contribution to its US sales from the respiratory portfolio, with anticipated revenues reaching around $300 million.

The company is working aggressively to reach margin of 20-23% soon, he said. The company's last quarter margin was at 18.7%.

| Lupin shares hit 52-week high after Nomura sees nearly 18% upside

He highlighted the huge opportunity for Lupin in specific drugs like the diabetes and obesity drug semaglutide, which is a big hit in the US market.

Price erosion in the US has slowed down, he said, adding that for Lupin the erosion would be in the low single-digits on a year on year basis

Also Read | Lupin's Swiss arm to acquire established products from Sanofi for Rs 91 crore

 

Headquartered in Mumbai, this multinational pharmaceutical firm from India boasts a market capitalisation of Rs 63,729.78 crore. The company emphasises various medical domains such as paediatrics, cardiovascular health, anti-infectives, diabetology, asthma, and anti-tuberculosis solutions.

For the entire interview, watch the accompanying video